JenaValve Technology, Inc. (“JenaValveor the “Company”), developer and manufacturer of differentiated transcatheter aortic valvereplacement (TAVR) systems, today announced the appointment of Kari Moore as theCompany’s CFO effective May 10th, 2022.

“We are excited to welcome Kari to the JenaValve team,” said John Kilcoyne, JenaValve’s CEO.“Kari brings over 35 years of extensive financial and operational experience in the medicaldevice and healthcare industry. Kari’s extensive knowledge and industry expertise will beinstrumental as we continue to execute our clinical strategy and move forward in ourcommercialization efforts of the Trilogy® Heart Valve System for the treatment of aortic valvediseases.”

Mrs. Moore joins JenaValve after most recently serving as the Chief Accounting Officer ofEnvista Holdings Corporation, a global dental products company, where she was responsible forthe worldwide accounting, treasury, and shared services functions. Prior to joining EnvistaHoldings Corporation, Mrs. Moore was the Chief Accounting Officer at Applied MedicalCorporation, a global medical device company providing technologies and solutions forminimally invasive and general surgery. Mrs. Moore began her carrier atPricewaterhouseCoopers, where she served as an audit partner and specialized in the lifesciences industry. Over her 20-year career, Mrs. Moore took many companies public andassisted them with acquisitions, divestitures, and debt offerings. Kari received a BS in BusinessAdministration from the University of Southern California and is a licensed CPA in the state ofCalifornia.

Mrs. Moore stated, “I am thrilled to be joining JenaValve at such a pivotal time. I am excited topartner with the entire JenaValve team to continue executing our growth and value creationstrategies while improving patients’ lives.”